- Strategy of antiaggregation treatment after percutaneous coronary interventions2012 | Third Faculty of Medicine
- Antiaggregating activity of arylalkane acids2003 | Faculty of Pharmacy in Hradec Králové
- Antiaggregation treatment - review of drugs, importance for clinical practice, and possibilities of determination of resistance to treatment2011 | Third Faculty of Medicine
- Anticoagulation, antiaggregation, inhibitors IIb/IIIa or fibrinolytics prior to primary PCI?2004 | First Faculty of Medicine
- Antioxidative and antiaggregating flavonoids from Leuzea carthamoidesPublication without faculty affiliation
- Synthesis and biological determination of 2',5'-diazachalcones VII.Antiaggregative activity2002 | Publication without faculty affiliation
- Propyl Gallate - new substance to monitoring of antiaggregation treatmentPublication without faculty affiliation
- Platelet antiaggregating activity of 2', 5' - diazachalcones2003 | Faculty of Pharmacy in Hradec Králové
- Platelet antiaggregating activity of 2',5'-diazachalcones2005 | Faculty of Pharmacy in Hradec Králové, Central Library of Charles University
- Anticoagulation and antiaggregation therapy in inflammatory bowel disease2017 | Third Faculty of Medicine
- Open foramen ovale and paradoxical embolisation - antiaggregation therapy, anticoagulation therapy or a closure?2003 | Publication without faculty affiliation
- Attenuated antiaggregation effects of magnetite nanoparticles in cerebrospinal fluid of people with Alzheimer's disease2010 | Third Faculty of Medicine
- Platelet antiaggregating activity of substituted (E)-3-(3-hydroxyphenyl)-1-pyrazin-2-ylprop-2-en-1-onesPublication without faculty affiliation
- Our experiences with CPG monitoring of antiaggregation treatment by ASA according to therapeutic dosagePublication without faculty affiliation
- Anticoagulation, antiaggregation, inhibitors IIb/IIIa or fibrinolytics prior to primary PCI?2004 | Faculty of Medicine in Hradec Králové
- Secondary prevention of coronary heart disease and peripheral artery disease combining antiaggregation and anticoagulation therapy. Expert consensus statement of the Czech Society of Cardiology, the Czech Society of Internal Medicine and the Czech Society of Angiology to the outcomes of COMPASS trial2019 | Third Faculty of Medicine, Faculty of Medicine in Pilsen, First Faculty of Medicine
- Secondary prevention of coronary heart disease and peripheral artery disease combining antiaggregation and anticoagulation therapy. Expert consensus statement of the Czech Society of Cardiology, the Czech Society of Internal Medicine and the Czech Society of Angiology to the outcomes of COMPASS trial2019 | Third Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen, First Faculty of Medicine
- Chalcones and their analogues as potential drugsPublication without faculty affiliation
- Antiplatelet therapy in patients with chronic anticoagulant therapy2019 | First Faculty of Medicine
- Laboratory monitoring of antithrombotic treatment2006 | Publication without faculty affiliation
- Laboratory monitoring of antithrombotic treatment +12006 | Faculty of Medicine in Hradec Králové
- Laboratory monitoring of antithrombotic treatment2006 | Faculty of Medicine in Hradec Králové
- Laboratory monitoring of antithrombotic treatment2006 | First Faculty of Medicine
- (+/-)-BIGI-3h: Pentatarget-Directed Ligand combining Cholinesterase, Monoamine Oxidase, and Glycogen Synthase Kinase 3 beta Inhibition with Calcium Channel Antagonism and Antiaggregating Properties for Alzheimer's Disease2021 | Publication without faculty affiliation
- Antithrombotic therapy in valvular heart disease and artificial valves2013 | Third Faculty of Medicine
- Protocols of antithrombotic therapy in a University Cardiocenter2013 | Third Faculty of Medicine
- Antiplatelet therapy2005 | Publication without faculty affiliation
- Antiplatelet therapy +12005 | Faculty of Medicine in Hradec Králové